sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY November 2014 | Archived Issues

FDA Warns About Lenalidomide, Duloxetine Hydrochloride

Pharmacy Focus

The U.S. Food and Drug Administration has issued warnings about the cancer drug lenalidomide and the antidepressant duloxetine hydrochloride.


Mark Your Calendar


Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.


Grand Rounds

Click here to view a schedule of all upcoming grand rounds.


Educational Schedule

Click the PDF link below to see the Department of Surgery's educational schedule.

Educational Schedule - November 2014 (PDF)


Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

FDA Warns About Lenalidomide, Duloxetine Hydrochloride

Pharmacy Focus

The U.S. Food and Drug Administration has issued warnings about the cancer drug lenalidomide and the antidepressant duloxetine hydrochloride.

Lenalidomide Poses Increased Risk of DVTs, Other Problems, FDA Says

The FDA said the cancer drug lenalidomide (Revlimid) demonstrated a significantly increased risk of deep vein thrombosis and pulmonary embolism, as well as risk of myocardial infarction and stroke in patients with multiple myeloma who were treated with lenalidomide and dexamethasone therapy.

For more information, click here.

Suicidal Thoughts More Likely in Younger Patients With Duloxetine Hydrochloride, FDA Warns

The FDA said antidepressants, including duloxetine hydrochloride (Cymbalta), increased the risk of suicidal thoughts and behavior in children, adolescents and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24, and there was a reduction in risk with antidepressant use in patients 65 and older.

For more information, click here.